UBS has upgraded Albemarle Corp (ALB) to a Buy rating from Neutral, effective December 4, 2025. The stock is currently priced at $127.52.
This upgrade reflects a more optimistic outlook on the company's prospects, suggesting improved fundamentals or business performance. Albemarle Corp operates in the chemicals industry, focusing on the development, manufacture, and marketing of chemicals for various sectors, including consumer electronics, petroleum refining, and pharmaceuticals. The company, headquartered in Charlotte, North Carolina, has a market capitalization of $14.9 billion and employs approximately 8,300 people.
Albemarle's upcoming earnings report is scheduled for July 28, 2026, with an estimated EPS of $0.13 and revenue of $1.3 billion. The company's recent earnings performance has shown significant surprises, including a Q3 2025 EPS of -0.19, which exceeded expectations by 75.9%.
Analyst consensus currently stands at Hold, with 4 Strong Buy, 7 Buy, 17 Hold, 2 Sell, and 1 Strong Sell ratings among 31 analysts. The move underscores a shift in sentiment towards Albemarle Corp as analysts reassess their views based on the latest developments.